|
| 36876335 | Reduction and prevention of agitation in persons with neurocognitive disorders: an international psychogeriatric association consensus algorithm. | Int Psychogeriatr | 2024 |
| 36880250 | Agitation in cognitive disorders: Progress in the International Psychogeriatric Association consensus clinical and research definition. | Int Psychogeriatr | 2024 |
| 36349985 | Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer's disease. | Alzheimers Dement | 2023 |
| 37798224 | Life-Course Brain Health as a Determinant of Late-Life Mental Health: American Association for Geriatric Psychiatry Expert Panel Recommendations. | Am J Geriatr Psychiatry | 2023 |
| 37538343 | Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study. | Alzheimers Dement (N Y) | 2023 |
| 37066690 | Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). | Int Psychogeriatr | 2023 |
| 36821370 | Dementia in the incarcerated population: a retrospective study using the South Carolina Alzheimer's disease registry, USA. | Int J Prison Health | 2023 |
| 32461027 | Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate. | Am J Geriatr Psychiatry | 2021 |
| 33514274 | Rivastigmine Transdermal Patch Treatment for Moderate to Severe Cognitive Impairment in Veterans with Traumatic Brain Injury (RiVET Study): A Randomized Clinical Trial. | J Neurotrauma | 2021 |
| 34661109 | Brain amyloid burden, sleep, and 24-hour rest/activity rhythms: screening findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration Studies. | Sleep Adv | 2021 |
| 34570180 | Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial. | JAMA Neurol | 2021 |
| 33949763 | Diagnostic criteria for apathy in neurocognitive disorders. | Alzheimers Dement | 2021 |
| 33458891 | Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI and dementia) in primary care: a review and synthesis. | J Intern Med | 2021 |
| 32565008 | Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of Instruments. | Am J Geriatr Psychiatry | 2021 |
| 30303050 | A retrospective, population-based cohort study of driving under the influence, Alzheimer's disease diagnosis, and survival. | Int Psychogeriatr | 2019 |
| 31637242 | Lifestyle Choices and Brain Health. | Front Med (Lausanne) | 2019 |
| 29347996 | The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial. | Trials | 2018 |
| 29969907 | Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease. | Am J Alzheimers Dis Other Demen | 2018 |
| 30400094 | Psychometric Properties of Apathy Scales in Dementia: A Systematic Review. | J Alzheimers Dis | 2018 |
| 30336111 | Perspective from Clinical Research: Ethical Issues in Alzheimer's Disease Research. | J Law Med Ethics | 2018 |
| 29616702 | Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force. | J Prev Alzheimers Dis | 2018 |
| 27855483 | Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of Hallucinations. | Am J Psychiatry | 2017 |
| 27032628 | Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study. | Am J Psychiatry | 2016 |
| 26303700 | Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences. | J Geriatr Psychiatry Neurol | 2016 |
| 26400852 | The neural correlates of anomia in the conversion from mild cognitive impairment to Alzheimer's disease. | Neuroradiology | 2016 |
| 26611790 | A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. | J Pharmacokinet Pharmacodyn | 2016 |
| 27145364 | R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. | Br J Clin Pharmacol | 2016 |
| 27115509 | Principal components analysis of agitation outcomes in Alzheimer's disease. | J Psychiatr Res | 2016 |
| 27567808 | Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease. | J Alzheimers Dis | 2016 |
| 26771737 | Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. | Am J Psychiatry | 2016 |
| 26736036 | Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease. | J Psychiatr Res | 2016 |
| 25101659 | Induction of salivary nerve growth factor by Yogic breathing: a randomized controlled trial. | Int Psychogeriatr | 2015 |
| 26362286 | A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. | Neurology | 2015 |
| 26305876 | Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. | Int Psychogeriatr | 2015 |
| 26393847 | Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. | JAMA | 2015 |
| 26238225 | Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. | Am J Geriatr Psychiatry | 2015 |
| 25311499 | Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. | Int Psychogeriatr | 2015 |
| 25355137 | The state of psychogeriatrics in Europe: challenges and opportunities in six European countries. | Int Psychogeriatr | 2015 |
| 23583234 | Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. | Alzheimers Dement | 2014 |
| 28911722 | Erratum to "Exploratory analysis of seven Alzheimer's disease genes: disease progression" [Neurobiol. Aging 34 (2013) 1310.e1-1310.e7]. | Neurobiol Aging | 2014 |
| 24914549 | Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial. | PLoS One | 2014 |
| 24549548 | Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. | JAMA | 2014 |
| 24314887 | Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2. | Am J Geriatr Psychiatry | 2014 |
| 24381967 | Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. | JAMA | 2014 |
| 24169147 | Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial. | Int Psychogeriatr | 2014 |
| 23895105 | Spinal cord injury: how can we improve the classification and quantification of its severity and prognosis? | J Neurotrauma | 2014 |
| 23036585 | Exploratory analysis of seven Alzheimer's disease genes: disease progression. | Neurobiol Aging | 2013 |
| 23845448 | The state of psychogeriatrics in different regions of the world: challenges and opportunities. | Int Psychogeriatr | 2013 |
| 24021498 | Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. | J Clin Psychiatry | 2013 |
| 23567407 | Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET). | Am J Geriatr Psychiatry | 2013 |